Ethyl Acetate Fractions of Tectona Grandis Crude Extract Modulate Glucose Absorption and Uptake as Well as Antihyperglycemic Potential in Fructose-Streptozotocin-Induced Diabetic Rats.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, [2000-

Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Experimental*/drug therapy ; Hyperglycemia*/drug therapy ; Acetates*; Animals ; Rats ; Hypoglycemic Agents/pharmacology ; Hypoglycemic Agents/therapeutic use ; Streptozocin ; Glucose ; Fructose ; Solvents

Type 2 diabetes (T2D) is a global health challenge with increased morbidity and mortality rates yearly. Herbal medicine has provided an alternative approach to treating T2D with limited access to formal healthcare. Tectona grandis is being used traditionally in the treatment of diabetes. The present study investigated the antidiabetic potential of T. grandis leaves in different solvent extractions, and the crude extract that demonstrated the best activity was further fractionated through solvent-solvent partitioning. The ethyl acetate fraction of the ethanol crude extract showed the best antidiabetic activity in inhibiting α-glucosidase, delaying glucose absorption at the small intestine's lumen, and enhancing the muscle's postprandial glucose uptake. The ethyl acetate fraction was further elucidated for its ability to reduce hyperglycemia in diabetic rats. The ethyl acetate fraction significantly reduced high blood glucose levels in diabetic rats with concomitant modulation in stimulated insulin secretions through improved pancreatic β-cell function, insulin sensitivity by increasing liver glycogen content, and reduced elevated levels of liver glucose-6-phosphatase activity. These activities could be attributed to the phytochemical constituents of the plant.

Anal Biochem. 1974 Apr;58(2):414-21. (PMID: 4827390)
Molecules. 2022 Jan 30;27(3):. (PMID: 35164215)
Mol Nutr Food Res. 2022 Nov;66(21):e2101113. (PMID: 35315210)
Anc Sci Life. 2013 Apr;32(4):241-4. (PMID: 24991074)
Diagn Pathol. 2013 Aug 15;8:137. (PMID: 23947821)
Nutr Metab Cardiovasc Dis. 2013 Oct;23(10):913-9. (PMID: 23786818)
Redox Biol. 2021 Jun;42:101920. (PMID: 33707127)
Food Chem. 2022 Nov 1;393:133443. (PMID: 35751216)
J Family Med Prim Care. 2022 Jan;11(1):27-31. (PMID: 35309606)
Asian Pac J Trop Med. 2011 Aug;4(8):624-31. (PMID: 21914540)
Eur J Pharmacol. 2018 Jan 5;818:115-123. (PMID: 29061371)
Antioxidants (Basel). 2019 Aug 01;8(8):. (PMID: 31374918)
J Clin Endocrinol Metab. 2020 Jan 1;105(1):. (PMID: 31513265)
Diabetes. 2010 Nov;59(11):2697-707. (PMID: 20705776)
Biomed Res Int. 2013;2013:382063. (PMID: 24307994)
J Clin Invest. 2019 Oct 1;129(10):4001-4008. (PMID: 31424428)
Molecules. 2017 May 30;22(6):. (PMID: 28556815)
Antioxidants (Basel). 2023 Mar 08;12(3):. (PMID: 36978912)
Pharm Biol. 2017 Dec;55(1):416-422. (PMID: 27937039)
Exp Mol Med. 2023 Aug;55(8):1652-1658. (PMID: 37524865)
Food Chem Toxicol. 2014 Apr;66:245-53. (PMID: 24491264)
BMC Complement Altern Med. 2015 Aug 06;15:265. (PMID: 26245866)
Int J Biol Macromol. 2022 May 1;206:567-579. (PMID: 35247420)
Ann N Y Acad Sci. 2018 Jan;1411(1):21-35. (PMID: 28868790)
Diabetes Res Clin Pract. 2019 Nov;157:107843. (PMID: 31518657)
World J Biol Chem. 2015 Feb 26;6(1):1-15. (PMID: 25717351)
Fitoterapia. 2014 Dec;99:1-6. (PMID: 25172103)
Biomed Pharmacother. 2018 Nov;107:306-328. (PMID: 30098549)
Nutrients. 2015 Jun 19;7(6):4995-5019. (PMID: 26102213)
Curr Diab Rep. 2010 Jun;10(3):184-91. (PMID: 20425581)
Am J Physiol Endocrinol Metab. 2018 Mar 1;314(3):E201-E205. (PMID: 29089337)
Nutrients. 2021 Jan 06;13(1):. (PMID: 33419065)
Biomed Pharmacother. 2018 Oct;106:1116-1125. (PMID: 30119178)
Pharmacol Rep. 2012;64(1):129-39. (PMID: 22580529)
Food Funct. 2015 Mar;6(3):955-62. (PMID: 25656339)
J Food Drug Anal. 2018 Jan;26(1):221-231. (PMID: 29389559)
Cells. 2023 Mar 20;12(6):. (PMID: 36980281)
Int J Mol Sci. 2019 Oct 18;20(20):. (PMID: 31635296)
Eur J Nutr. 2018 Feb;57(1):279-295. (PMID: 27757592)
Analyst. 2002 Jan;127(1):183-98. (PMID: 11827390)
Nutr Res. 2016 Jul;36(7):710-8. (PMID: 27262537)
Pharm Biol. 2016 Aug;54(8):1326-33. (PMID: 26439719)
PLoS One. 2011;6(9):e25338. (PMID: 21966503)
Clin Sci (Lond). 2015 Nov;129(10):839-50. (PMID: 26201094)
Molecules. 2021 Jan 29;26(3):. (PMID: 33572808)
Pharmaceuticals (Basel). 2010 Sep 15;3(9):3005-3020. (PMID: 27713388)
Int J Mol Sci. 2020 Aug 30;21(17):. (PMID: 32872570)
Cell Metab. 2021 Apr 6;33(4):709-720. (PMID: 33765416)
Int J Mol Sci. 2011;12(6):3757-69. (PMID: 21747704)
Kidney Blood Press Res. 2020;45(1):131-141. (PMID: 31865342)
Diabetes Care. 2001 Feb;24(2):382-91. (PMID: 11213896)

PSID2203301202 National Research Foundation

Keywords: Tectona grandis; glucose tolerance; hyperglycemia; pancreatic β cell

0 (Hypoglycemic Agents)
5W494URQ81 (Streptozocin)
76845O8NMZ (ethyl acetate)
IY9XDZ35W2 (Glucose)
30237-26-4 (Fructose)
0 (Solvents)
0 (Acetates)

Date Created: 20240111 Date Completed: 20240112 Latest Revision: 20240113

20240113

PMC10778942

10.3390/ijms25010028

38203195